Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares insights into a recent publication exploring the use of immune single-cell sequencing (SCS) as a prognostic tool in patients with smoldering multiple myeloma (SMM) treated with immunotherapy. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.